Improving treatment outcomes for children with acute lymphoblastic leukemia using new targeted therapies.
Official title: Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease
Funded at University of Colorado Denver · NIH-10849945 · Data updated 2026-11-12
This study is looking to improve treatment for kids and young adults with acute lymphoblastic leukemia by testing new therapies to see how well they work and who might benefit the most from them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $172,013 |
| NIH project number | 1R50CA288324-01 |
| Project ID | NIH-10849945 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and young adults diagnosed with acute lymphoblastic leukemia, particularly those with high-risk or relapsed disease.
✕Less likely to help
Patients with other types of leukemia or those who are not within the pediatric age range may not benefit from this research.
What this research studies
This research focuses on enhancing the treatment of pediatric acute lymphoblastic leukemia (ALL) by integrating novel targeted therapies into the care of children, adolescents, and young adults. The approach involves conducting clinical trials through the National Clinical Trials Network, specifically the Children’s Oncology Group, to evaluate the effectiveness of new therapies for both newly diagnosed and relapsed cases. The research aims to better understand the toxicities associated with these therapies and to identify patients who may benefit the most based on their individual clinical and genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced side effects for children suffering from acute lymphoblastic leukemia.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies in treating acute lymphoblastic leukemia, indicating a potential for success in this novel approach.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: O'brien, Maureen Megan — University of Colorado Denver
- Study coordinator: O'brien, Maureen Megan
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.